CORR Insights ®: Synovial Sarcoma Is Not Associated With a Higher Risk of Lymph Node Metastasis Compared With Other Soft Tissue Sarcomas.

CORR Insights®: Synovial Sarcoma Is Not Associated With a Higher Risk of Lymph Node Metastasis Compared With Other Soft Tissue Sarcomas. Clin Orthop Relat Res. 2018 Mar;476(3):599-600 Authors: Greenberg DD PMID: 29529648 [PubMed - in process]
Source: Clinical Orthopaedics and Related Research - Category: Orthopaedics Authors: Tags: Clin Orthop Relat Res Source Type: research

Related Links:

Abstract: Synovial sarcoma (SS) is a high-grade soft-tissue sarcoma occurring predominantly in older children and young adults. Only approximately 7% occur in the head and neck region, with SS representing less than 0.1% of all head and neck cancers. Orbital location is exceedingly rare with only 8 cases reported so far in the literature. It is noted for its propensity for late local recurrences and metastases. Histologically, SS is monophasic, biphasic, or poorly differentiated and harbors a specific chromosomal translocation t(X;18)(p11.2;q11.2) in>95% of cases. In this article, we describe a case of monophasic SS p...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Brief Report Source Type: research
Introduction: Synovial sarcomas are an aggressive type of sarcoma, constituting approximately 10% of all soft tissue sarcomas. They are most common on the extremities with a mean age of 30 years at diagnosis. Although synovial sarcomas are typically localized at the time of diagnosis, they metastasize more frequently than other soft tissue sarcomas to the lungs, lymph nodes and bone.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Authors: Duran-Moreno J, Kontogeorgakos V, Koumarianou A Abstract Soft tissue sarcomas (STS) are rare tumors; they do not even equate to 1% of all malignant tumor cases. One-fifth of all STS occur in the upper extremities, where epithelioid sarcoma, synovial sarcoma, clear cell sarcoma and malignant fibrohistiocytoma are the most frequent subtypes. Surgical resection is the cornerstone of treatment. However, accomplishment of optimal oncological and functional results of STS of the upper extremities may represent a challenge for hand surgeons, due to the complex anatomy. In several cases, preoperative therapies are...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Publication date: Available online 2 July 2019Source: Pharmacology &TherapeuticsAuthor(s): Elizabeth Thoenen, Amanda Curl, Tomoo IwakumaAbstractGenomic and functional study of existing and emerging sarcoma targets, such as fusion proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic drivers, is broadening our understanding of sarcomagenesis. Among these mechanisms, the tumor suppressor p53 (TP53) plays significant roles in the suppression of bone and soft tissue sarcoma progression. Although mutations in TP53 were thought to be relatively low in sarcomas, modern techniques including whole-...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
lay Frédéric Chibon Soft-tissue sarcomas (STS) are rare tumors whose oncogenesis remains unknown and for which no common therapeutic target has yet been identified. Analysis of 318 STS by CGH array evidenced a frequent deletion affecting the DMD gene (encoding dystrophin isoforms) in 16.5% of STS, including sarcomas with complex genomics, gastrointestinal tumors (GIST), and synovial sarcomas (SS). These deletions are significantly associated with metastatic progression, thus suggesting the role of DMD downregulation in the acquisition of aggressive phenotypes. We observed that targeted deletions of DMD ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion.This phase II study met its primary endpoint with an 18‐week DCR of 46%. The clinical activity of dacarbazine plus sorafenib in patients with these diagnoses is modest.Implications for Practice.Metastatic soft tissue sarcomas are a heterogeneous group of relatively rare malignancies. Most patients are treated with cytotoxic chemotherapy or targeted therapy in the form of tyrosine kinase inhibitors. Response rates are relatively low, and there is a need for better therapies. This clinical trial demonstrates that combining a cytotoxic therapy (dacarbazine) with an antiangiogenic small molecule (sorafenib) is fea...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Sarcomas Source Type: research
Abstract Synovial sarcoma (SS) is an aggressive subgroup of soft tissue sarcoma (STS) with high grade and high risk of metastasis. However, there are no systemic therapies available that target SS. Therefore, transformative therapy is needed for SS. To establish a patient-derived orthotopic xenograft (PDOX) model, a patient tumor with high grade SS from a lower extremity was grown orthotopically in the right biceps femoris muscle of mice. To test the efficacy of drugs, the PDOX models were randomized into five groups: Group 1 (G1), control-without treatment; Group 2 (G2), doxorubicin (DOX); Group 3 (G3), temozolom...
Source: Tissue and Cell - Category: Cytology Authors: Tags: Tissue Cell Source Type: research
Conclusion SUVmax seems to be specific among different STS histotypes. PET does not seem to be useful in myxoid liposarcoma as well as synovial sarcoma as these tumours seem to have a low uptake of glucose. SUVmax might also be included as a prognostic factor.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
1295Introduction: Three-dimensional (3-D) displays for medical imaging is emerging field and very promising tools for diagnosis, therapy response and detection of tumor recurrence. Morphological criteria for therapy response (CR, PR, SD, PD) have been established with RECIST (Response evaluation criteria in solid tumors). With adoption of metabolic imaging with PET/CT, particularly with F-18-FDG in initial staging and follow up of tumors, there appears to be a need to modify these criteria not only on morphological imaging modalities like CT, but also on tumor metabolism parameters, like SUV (standardized uptake value) as ...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Musculoskeletal Posters Source Type: research
ConclusionsUCP1 is strongly expressed in BAT but not WAT and is found in all hibernomas and a few pleomorphic liposarcomas but not in other adipose tumours. UCP1 expression in a few non-adipose soft tissue sarcomas may possibly reflect origin of tumour cells from a common mesenchymal stem cell precursor and/or developmental pathway.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Orthopaedics | Sarcomas | Soft Tissue Sarcoma | Synovial Sarcoma